Objective and Subjective Bronchodilation over 12 Hours After Inhaled Formoterol: Individual Responses
- 1 January 1993
- journal article
- clinical trial
- Published by Taylor & Francis in Journal of Asthma
- Vol. 30 (6) , 459-465
- https://doi.org/10.3109/02770909309056755
Abstract
The aim of the present study was to compare the duration of bronchodilation obtained with 12 micrograms formoterol and 24 micrograms formoterol with that of 200 micrograms salbutamol over 12 hr. Thirteen stable asthmatics (mean age 59 years, asthma duration 7 years, mean FEV1 56% predicted, and reversibility to beta-adrenoceptor stimulation 36%) were studied in a double-blind crossover study. Lung function test (FEV1 and FVC), heart rate, tremor, and subjective effects were recorded before and 30 min after the test doses and every hour up to 12 hr. The test doses were randomized and given double-blindly as two puffs using a spacer. The median duration of effect, defined as time when FEV1 fell below 20% the maximum bronchodilating capacity, was longer than 12 hr for both formoterol doses, whereas it was 7 hr for salbutamol (p < 0.01). No difference between the two doses of formoterol was seen. The median of the patients' subjective evaluation of the duration of effect was 12 hr, more than 12 hr for 12 and 24 micrograms formoterol, respectively, and 8 hr for salbutamol (p < 0.01). Only 1 patient needed rescue medication on the 2 formoterol days. However, 6 patients inhaled rescue medication during treatment with salbutamol. There were no differences with regard to heart rate, blood pressure, subjective tremor, or palpitations. Formoterol, 12 micrograms and 24 micrograms, was shown to produce at least 12 hr of bronchodilating effect in most patients. However, there was considerable individual variation in duration of effect.Keywords
This publication has 13 references indexed in Scilit:
- A Three-Month Comparison of Twice Daily Inhaled Formoterol Versus Four Times Daily Inhaled Albuterol in the Management of Stable AsthmaAmerican Review of Respiratory Disease, 1991
- Prolonged Protection against Methacholine-induced Bronchoconstriction by the Inhaled β2-Agonist FormoterolAmerican Review of Respiratory Disease, 1991
- Formoterol, a new long-acting selectiveβ 2-agonist, decreases airway responsiveness in children with asthmaLung, 1990
- Formoterol in the Treatment of Nocturnal AsthmaChest, 1990
- Twelve hours' bronchodilating effect of inhaled formoterol in children with asthma: a double‐blind cross‐over study versus salbutamolClinical and Experimental Allergy, 1990
- Formoterol, a new long acting beta 2 agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma.Thorax, 1990
- Bronchodilator Effect of Inhaled Formoterol vs Salbutamol Over 12 HoursChest, 1990
- Formoterol fumarate, a new β2‐adrenoceptor agonistAllergy, 1989
- Formoterol and salbutamol metered aerosols: Comparison of a new and an established beta‐2‐agonist for their bronchodilating efficacy in the treatment of childhood bronchial asthmaPediatric Pulmonology, 1989
- Comparison of cumulative and non-cumulative techniques to measure dose-response curves for beta agonists in patients with asthma.Thorax, 1984